Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has been granted a worldwide license to Schering AG's ADP receptor agonist program, under which Pfizer will have exclusive rights to develop and market oral compounds as potential treatments for blood clots, stroke and heart attack.
Subscribe to our email newsletter
Although specific financial terms were not announced, Schering will receive an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized under the agreement.
ADP receptor antagonists are anti-platelet agents that can be used to chronically inhibit arterial thrombosis (formation of blood clots in the arteries) and prevent stroke and heart attack in patients at high risk for cardiovascular events. This high-risk group includes patients with previous stroke, heart attack or established peripheral arterial disease.
The acquisition of exclusive, worldwide rights to this program will provide Pfizer with an opportunity to strengthen its presence in the cardiovascular disease market, which is already supported by leading medicines such as Lipitor and Norvasc.